Cite

HARVARD Citation

    Kapp, K. et al. (2019). EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy. Journal for immunotherapy of cancer. 7 (1), p. . [Online]. 
  
Back to record